TRK Inhibitor Activity and Resistance in TRK Fusion-positive Cancers in Adults

Overview

Journal Cancer Genet

Publisher Elsevier

Specialty Oncology

Date 2022 Mar 25

PMID 35334340

Authors

Guilherme Harada

Alexander Drilon

Affiliations

Soon will be listed here.

Abstract

NTRK fusions drive oncogenesis in a variety of adult cancers. The approval of the first-generation TRK inhibitors, larotrectinib and entrectinib, for any cancer with an NTRK fusion represented a focal point in tumor-agnostic drug development. These agents achieve high response rates and durable disease control, and display intracranial activity. The use of these agents has resulted in a deeper understanding of the clinical consequences of TRK inhibition. These on-target side effects include dizziness, weight gain, and withdrawal pain. The study of TRK inhibitor resistance led to the development of next generation drugs, such as selitrectinib, repotrectinib, taletrectinib, and other agents that maintain disease control against selected acquired kinase domain mutations. This review discusses the clinical efficacy of TRK inhibitors, their safety profiles, and resistance mechanisms with a focus on data in adult cancers.

Citing Articles

Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy.

Marczyk V, Fazeli S, Dadu R, Busaidy N, Iyer P, Hu M JCO Precis Oncol. 2025; 9:e2400321.

PMID: 39983078 PMC: 11867807. DOI: 10.1200/PO.24.00321.

Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions.

Gouda M, Thein K, Hong D Cancers (Basel). 2024; 16(19).

PMID: 39410015 PMC: 11475940. DOI: 10.3390/cancers16193395.

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.

Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E Br J Cancer. 2024; 131(3):601-610.

PMID: 38902532 PMC: 11300601. DOI: 10.1038/s41416-024-02760-1.

Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer.

Mariella E, Grasso G, Miotto M, Buzo K, Reilly N, Andrei P Mol Oncol. 2024; 18(6):1460-1485.

PMID: 38468448 PMC: 11161737. DOI: 10.1002/1878-0261.13622.

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.

Xiang S, Lu X Acta Pharm Sin B. 2024; 14(2):517-532.

PMID: 38322338 PMC: 10840435. DOI: 10.1016/j.apsb.2023.11.010.

References

Vaishnavi A, Capelletti M, Le A, Kako S, Butaney M, Ercan D . Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013; 19(11):1469-1472. PMC: 3823836. DOI: 10.1038/nm.3352. View

Fischer H, Ullah M, de la Cruz C, Hunsaker T, Senn C, Wirz T . Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol. 2020; 22(6):819-829. PMC: 7283026. DOI: 10.1093/neuonc/noaa052. View

Pulciani S, Santos E, Lauver A, Long L, Aaronson S, Barbacid M . Oncogenes in solid human tumours. Nature. 1982; 300(5892):539-42. DOI: 10.1038/300539a0. View

Awad M, Katayama R, McTigue M, Liu W, Deng Y, Brooun A . Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013; 368(25):2395-401. PMC: 3878821. DOI: 10.1056/NEJMoa1215530. View

Doebele R, Drilon A, Paz-Ares L, Siena S, Shaw A, Farago A . Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2019; 21(2):271-282. PMC: 7461630. DOI: 10.1016/S1470-2045(19)30691-6. View

Drilon A, Ou S, Cho B, Kim D, Lee J, Lin J . Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov. 2018; 8(10):1227-1236. DOI: 10.1158/2159-8290.CD-18-0484. View

Doebele R, Davis L, Vaishnavi A, Le A, Estrada-Bernal A, Keysar S . An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015; 5(10):1049-57. PMC: 4635026. DOI: 10.1158/2159-8290.CD-15-0443. View

Indo Y, Tsuruta M, Hayashida Y, Karim M, Ohta K, Kawano T . Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet. 1996; 13(4):485-8. DOI: 10.1038/ng0896-485. View

Park K, Yu C, Kim S, Lin M, Sriuranpong V, Tsai C . First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. JAMA Oncol. 2016; 2(3):305-12. DOI: 10.1001/jamaoncol.2015.4921. View

10.

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R . Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016; 15(4):628-39. DOI: 10.1158/1535-7163.MCT-15-0758. View

11.

Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin J . NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer. 2021; 126(3):514-520. PMC: 8811064. DOI: 10.1038/s41416-021-01536-1. View

12.

Cocco E, Scaltriti M, Drilon A . NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018; 15(12):731-747. PMC: 6419506. DOI: 10.1038/s41571-018-0113-0. View

13.

Hong D, Dubois S, Kummar S, Farago A, Albert C, Rohrberg K . Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020; 21(4):531-540. PMC: 7497841. DOI: 10.1016/S1470-2045(19)30856-3. View

14.

LYONS W, Mamounas L, Ricaurte G, Coppola V, Reid S, Bora S . Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A. 1999; 96(26):15239-44. PMC: 24804. DOI: 10.1073/pnas.96.26.15239. View

15.

Cocco E, Lee J, Kannan S, Schram A, Won H, Shifman S . TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discov. 2020; 11(1):126-141. PMC: 8012405. DOI: 10.1158/2159-8290.CD-20-0571. View

16.

Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

17.

Omote S, Matsuoka N, Arakawa H, Nakanishi T, Tamai I . Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1. Sci Rep. 2018; 8(1):9237. PMC: 6006426. DOI: 10.1038/s41598-018-27672-y. View

18.

Cocco E, Schram A, Kulick A, Misale S, Won H, Yaeger R . Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med. 2019; 25(9):1422-1427. PMC: 6736691. DOI: 10.1038/s41591-019-0542-z. View

19.

Gray J, Yeo G, Hung C, Keogh J, Clayton P, Banerjee K . Functional characterization of human NTRK2 mutations identified in patients with severe early-onset obesity. Int J Obes (Lond). 2006; 31(2):359-64. DOI: 10.1038/sj.ijo.0803390. View

20.

Roskoski Jr R . Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2015; 103:26-48. DOI: 10.1016/j.phrs.2015.10.021. View